Managing dyspepsia

Current Gastroenterology Reports

Volumn 11, Issue 4, 2009, Pages 288-294

  Ford, Alexander C ^a   Moayyedi, Paul ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIDEPRESSANT AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PLACEBO; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

ABDOMINAL MASS; ABDOMINAL PAIN; AGE DISTRIBUTION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; COMMUNITY CARE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIGESTIVE SYSTEM CANCER; DRUG COST; DRUG EFFICACY; DUODENUM ULCER; DYSPEPSIA; DYSPHAGIA; ENDOSCOPY; FAMILY HISTORY; HEALTH CARE COST; HELICOBACTER INFECTION; HEMATEMESIS; HUMAN; INCIDENCE; IRON DEFICIENCY ANEMIA; MELENA; ODYNOPHAGIA; PEPTIC ULCER; PREVALENCE; RECURRENT DISEASE; REVIEW; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; STOMACH ULCER; UPPER GASTROINTESTINAL ENDOSCOPY; VOMITING; WEIGHT REDUCTION;

ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; DYSPEPSIA; ENDOSCOPY, GASTROINTESTINAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; PEPTIC ULCER; PREVALENCE; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 67849124706     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-009-0042-2     Document Type: Review

References (54)

1. Ford AC, Marwaha A, Lim A, et al.: Prevalence of clinically significant endoscopic findings in individuals with and without dyspepsia: systematic review and meta-analysis [abstract]. Gastroenterology 2009, 136(Suppl 1): A488.
2. Colin-Jones DG, Bloom B, Bodemar G, et al.: Management of dyspepsia: report of a working party. Lancet 1988, 331: 576-579.
3. Talley NJ, ColinAJones DG, Koch KL, et al.: Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterology Intl 1991, 4: 145-160.
4. Tack J, Talley NJ, Camilleri M, et al.: Functional gastroduodenal disorders. Gastroenterology 2006, 130: 1466-1479.
5. Agreus L, Svardsudd K, Nyren O, et al.: Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time. Gastroenterology 1995, 109: 671-680.
6. Moayyedi P, Forman D, Braunholtz D, et al.: The proportion of upper gastrointestinal symptoms in the community associated with Helicobacter pylori, lifestyle factors, and nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 2000, 95: 1448-1455.
7. Koloski NA, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol 2000, 95: 67-71.
8. Ford AC, Forman D, Bailey AG, et al.: Initial poor quality of life and new onset of dyspepsia: Results from a longitudinal 10-year follow-up study. Gut 2007, 56: 321-327.
9. Minocha A, Chad W, Do W, et al.: Racial differences in epidemiology of irritable bowel syndrome alone, un-investigated dyspepsia alone, and "overlap syndrome" among African Americans compared to Caucasians: A population-based study. Dig Dis Sci 2006, 51: 218-226.
10. Ford AC, Forman D, Bailey AG, et al.: Fluctuation of gastrointestinal symptoms in the community: A 10-year longitudinal follow-up study. Aliment Pharmacol Ther 2008, 28: 1013-1020.
11. Ford AC, Forman D, Bailey AG, et al.: Who consults with dyspepsia? Results from a longitudinal ten-year follow-up study. Am J Gastroenterol 2007, 102: 957-965.
12. Talley NJ, Zinsmeister AR, Schleck CD, et al.: Dyspepsia and dyspepsia subgroups: A population-based study. Gastroenterology 1992, 102: 1259-1268.
13. Penston JG, Pounder RE: A survey of dyspepsia in Great Britain. Aliment Pharmacol Ther 1996, 10: 83-89.
14. Levin TR, Schmittdiel JA, Kunz K, et al.: Costs of acid-related disorders to a health maintenance organization. Am J Med 1997, 103: 520-528.
15. Moayyedi P, Mason J: Clinical and economic consequences of dyspepsia in the community. Gut 2002, 50(Suppl 4): 10-12.
16. Talley NJ, Vakil NB, Moayyedi P: American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology 2005, 129: 1756-1780.
17. NatioMal Institute for Clinical Excellence: Dyspepsia: managing dyspepsia in adults in primary care. Available at http://www.nice.org.uk/ nicemedia/pdf/CG017fullguideline.pdf 2004. Accessed April 2009.
18. Talley NJ, Vakil N, Practice Parameters Committee of the American College of Gastroenterology: Guidelines for the management of dyspepsia. Am J Gastroenterol 2005, 100: 2324-2337.
19. Vakil N, Moayyedi P, Fennerty MB, et al.: Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology 2006, 131: 390-401.
20. El-Serag H, Sonnenberg A: Opposing time trends of peptic ulcer and reflux disease. Gut 1998, 43: 327-333.
21. Nomura A, Stemmerman GN, Chyou P-H, et al.: Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 1994, 120: 977-981.
22. Sonnenberg A, Schwartz JS, Cutler AF, et al.: Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: Results of a randomized, double-blind, multicenter trial. Arch Intern Med 1998, 158: 852-860.
23. Ford AC, Delaney BC, Forman D, et al.: Eradication therapy in Helicobacter pylori positive peptic ulcer disease: Systematic review and economic analysis. Am J Gastroenterol 2004, 99: 1833-1855.
24. Rauws EAJ, Langenberg W, Houthoff HJ, et al.: Campylobacter pyloridis-associated chronic active antral gastritis: A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988, 94: 33-40.
25. Laine L, Schoenfeld P, Fennerty MB: Therapy for Helicobacter pylori in patients with non-ulcer dyspepsia: A meta-analysis of randomized, controlled trials. Ann Intern Med 2001, 134: 361-369.
26. Moayyedi P, Soo S, Deeks JJ, et al.: Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Br Med J 2000, 321: 659-664.
27. Moayyedi P, Deeks J, Talley NJ, et al.: An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in non-ulcer dyspepsia: Resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003, 98: 2621-2626.
28. Moayyedi P, Soo S, Deeks J, et al.: Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006, (2): CD002096.
29. Moayyedi P, Soo S, Deeks J, et al.: Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006, (4): CD001960.
30. Abraham NS, Moayyedi P, Daniels B, et al.: The methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia. Aliment Pharmacol Ther 2004, 19: 631-641.
31. Moayyedi P, Delaney BC, Vakil N, et al.: The efficacy of proton pump inhibitors in non-ulcer dyspepsia: A systematic review and economic analysis. Gastroenterology 2004, 127: 1329-1337.
32. Ford AC, Talley NJ, Schoenfeld PS, et al.: Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: Systematic review and meta-analysis. Gut 2009, 58: 367-378.
33. Soo S, Moayyedi P, Deeks JJ, et al.: Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005, (2): CD002301.
34. Arents NLA, Thijs JC, van Zwet AA, et al.: Approach to treatment of dyspepsia in primary care: A randomized trial comparing 'test and treat' with prompt endoscopy. Arch Intern Med 2003, 163: 1606-1612.
35. Bytzer P, Hansen JM, Schaffalitzky de Muckadell OB: Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994, 343: 811-816.
36. Delaney BC, Wilson S, Roalfe A, et al.: Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: A randomised controlled trial in primary care. Lancet 2000, 356: 1965-1969.
37. Delaney BC, Wilson S, Roalfe A, et al.: Randomised controlled trial of Helicobacter pylori testing and endoscopy for dyspepsia in primary care. Br Med J 2001, 322: 898-901.
38. Duggan AE,AElliott CA, Miller P, et al.: Clinical trial: a randomized trial of endoscopy, Helicobacter pylori testing and empirical therapy for the management of dyspepsia in primary care. Aliment Pharmacol Ther 2009, 29: 55-68.
39. Jarbol DE, Kragstrup J, Stovring H, et al.: Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial. Am J Gastroenterol 2006, 101: 1200-1208.
40. Lassen AT, Pedersen FM, Bytzer P, et al.: Helicobacter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. Lancet 2000, 356: 455-460.
41. Lewin van den Broek NT, Numans ME, Buskens E, et al.: A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome. Br J Gen Pract 2001, 51: 619-624.
42. McColl KEL, Murray LS, Gillen D, et al.: Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H. pylori testing alone in the management of dyspepsia. Br Med J 2002, 324: 999-1002.
43. Ford AC, Qume M, Moayyedi P, et al.: Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia? An individual patient data meta-analysis. Gastroenterology 2005, 128: 1838-1844.
44. Ford AC, Moayyedi P, Jarbol DE, et al.: Meta-analysis: Helicobacter pylori "test and treat" compared with empirical acid suppression for managing dyspepsia. Aliment Pharmacol Ther 2008, 28: 534-544.
45. Lassen AT, Hallas J, Schaffalitzky de Muckadell OB: Helicobacter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients: 6.7 year follow-up of a randomised controlled trial. Gut 2004, 53: 1758-1763.
46. Delaney BC, Qume M, Moayyedi P, et al.: Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: Multi-centre randomised controlled trial (MRC-CUBE trial). Br Med J 2008, 336: 651-654.
47. van Marrewijk CJ, Mujakovic S, Fransen GAJ, et al.: Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): A primary-care-based randomised controlled trial. Lancet 2009, 373: 215-225.
48. Raghunath AS, Hungin AP, Mason J, et al.: Helicobacter pylori eradication in long-term proton pump inhibitor users in primary care: A randomized controlled trial. Aliment Pharmacol Ther 2007, 25: 585-592.
49. Helicobacter and Cancer Collaborative Group: Gastric cancer and Helicobacter pylori: A combined analysis of 1 2 case control studies nested within prospective cohorts. Gut 2001, 49: 347-353.
50. Lane JA, Murray LJ, Noble S, et al.: Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol Helicobacter project: Randomised controlled trial. Br Med J 2006, 332: 199-202.
51. Moayyedi P, Feltbower R, Brown J, et al.: Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: A randomised controlled trial. Lancet 2000, 355: 1665-1669.
52. Mason J, Axon ATR, Forman D, et al.: The cost-effectiveness of population Helicobacter pylori screening and treatment: A Markov model using economic data from a randomised controlled trial. Aliment Pharmacol Ther 2002, 16: 559-568.
53. Ford AC, Forman D, Bailey AG, et al.: A community screening program for Helicobacter pylori saves money: Ten-year follow-up of a randomised controlled trial. Gastroenterology 2005, 129: 1910-1917.
54. Talley NJ, Fock KM, Moayyedi P: Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol 2008, 103: 510-514.